ADC Therapeutics (ADC Therapeutics) Investments And Advances : $1.65 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is ADC Therapeutics Investments And Advances?

ADC Therapeutics's Investments And Advances for the quarter that ended in Dec. 2023 was $1.65 Mil.

ADC Therapeutics's quarterly Investments And Advances declined from Jun. 2023 ($28.32 Mil) to Sep. 2023 ($26.99 Mil) and declined from Sep. 2023 ($26.99 Mil) to Dec. 2023 ($1.65 Mil).

ADC Therapeutics's annual Investments And Advances declined from Dec. 2021 ($41.24 Mil) to Dec. 2022 ($7.61 Mil) and declined from Dec. 2022 ($7.61 Mil) to Dec. 2023 ($1.65 Mil).

ADC Therapeutics Investments And Advances Historical Data

The historical data trend for ADC Therapeutics's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ADC Therapeutics Investments And Advances Chart

ADC Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Investments And Advances

Get a 7-Day Free Trial

47.91

41.24

7.61

1.65

ADC Therapeutics Quarterly Data
	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Investments And Advances	Get a 7-Day Free Trial															7.61	29.53	28.32	26.99	1.65

ADC Therapeutics Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.

ADC Therapeutics (ADC Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ADC Therapeutics SA (NYSE:ADCT) » Definitions » Investments And Advances

Comparable Companies

Traded in Other Exchanges

N/A

Address

Route de la Corniche 3B, Biopole, Epalinges, CHE, 1066

Website

https://www.adctherapeutics.com

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.